Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Clinical Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Cor Vasa1
Search Results
Sort by
- BookJody Ranck, editor.Contents:
Chapter 1: Introduction to Digital Health
Chapter 2: Overview of the Digital Health Ecosystem
Chapter 3: Diabetes and the Telcare Solution (Jonathan Javitt, Telcare)
Chapter 4: Cooperation in Aging Services Technologies
Chapter 5: The Quantified Self, Wearables, and the Tracking Revolution
Chapter 6: Beyond Silos to Data Analytics for Population Health: Case Study of HealthBank and Citizen Coops for Health Data Transactions
Chapter 7: Healthcare Lessons From the Telecommunications Sector (Sven Schuchardt, Detecon)
Chapter 8: Smart Healthy Cities: Public-Private Partnerships, a Case From Telefonica in Brazil [Jody Ranck, Katia Galvane (Telefonica), Washington Tavares (ISPM)]
Chapter 9: Smart Digital Health Policies (Ticia Gerber, HL7)
Chapter 10: Cooperation for Building Secure Standards for Health Data (Cem Senturk, Detecon)
Chapter 11: Peer to Peer Platforms for Physicians in Underserved Areas: A Human Rights Approach to Social Media in Medicine: The Case of Tabeeb (Osama Alshaykh).Digital Access Springer 2016 - ArticleChlebus H, Jarecki M, Waclawek J, Kadzielawa R.Cor Vasa. 1977;19(1):1-11.The value of practolol in the treatment of angina pectoris was studied in three groups of patients by means of different methods. In 23 patients the effect of the drug was evaluated during long-term treatment and in 10 patients in a controlled double-blind trial; in 20 patients, the working capacity was determined by an ECG exercise test on a bicycle ergometer. Long-term treatment revealed advantageous effects of practolol on the incidence of anginal attacks and the number of nitroglycerin tablets consumed in daily life. There was also a noticeable improvement in the ECG. The results obtained in a double-blind trial, with placebo, proved the effectiveness of the drug. The treatment enabled the patients to lead appreciably more active lives. A marked increase in work performance, depending on the dose applied, was confirmed in exercise tolerance tests. No side-effects which would call for discontinuance of the treatment were seen during long-term administration with doses up to 800 mg daily.